((自动化翻译由路透提供，请见免责声明 ))
4月3日 - ** ARCA生物制药公司 股价盘前大涨约87%至3.2美元
** 公司将与私营生物技术公司 Oruka Therapeutics 以全股票交易方式合并
** Oruka 获得了由 Fairmount 和 Venrock Healthcare Capital Partners 领导的医疗保健投资者集团提供的 2.75 亿美元股票和认股权证资金，以支持这项交易。
** 合并后的新公司将以 Oruka Therapeutics 的名义运营，并在纳斯达克交易，股票代码为 "ORKA"。
** 交易完成时的现金余额预计将资助 Oruka 运营至 2027 年
** 现金余额将用于支持Oruka候选实验药物ORKA-001和ORKA-002的开发，作为慢性皮肤病的潜在治疗药物
** ABIO股东将拥有合并后公司约2.4%的股份，Oruka股东和投资者将拥有其余股份。
** 截至上一交易日收盘，ABIO 年累计上涨约 1
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.